Noticias de CRDF_US

27/04/2026 CRDF_US — GuruFocus ES ← EN

Transcripción de la conferencia Cardiff Oncology Inc en TD Cowen Healthcare

Cardiff Oncology Inc at TD Cowen Healthcare Conference Transcript

27/04/2026 CRDF_US — GlobeNewswire

Cardiff Oncology to Host Key Opinion Leader Discussion on Onvansertib’s Promising Single-Agent Activity

SAN DIEGO, 27 de abril de 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), una empresa de biotecnología en etapa clínica que aprovecha la inhibición de PLK1 para...

27/04/2026 CRDF_US — Stock Titan

Mayo Clinic leukemia expert joins Cardiff webinar on CMML drug data

La transmisión web comienza a las 11 a. m., hora del Este, el 30 de abril y cubre los datos del ensayo CMML iniciado por investigadores sobre onvansertib. La repetición se publicará después del evento.

27/04/2026 CRDF_US — Yahoo Finance

Cardiff Oncology to Host Key Opinion Leader Discussion on Onvansertib’s Promising Single-Agent Activity

26/04/2026 CRDF_US — MSN

Cardiff Oncology (CRDF) price target decreased by 17.38% to 8.74

26/04/2026 CRDF_US — MSN ES ← EN

El precio objetivo de Cardiff Oncology (CRDF) disminuyó un 17,38 % hasta 8,74

Cardiff Oncology (CRDF) price target decreased by 17.38% to 8.74

24/04/2026 CRDF_US — MSN ES ← EN

El precio objetivo de Cardiff Oncology (CRDF) disminuyó un 17,38 % hasta 8,74

Cardiff Oncology (CRDF) price target decreased by 17.38% to 8.74

23/04/2026 CRDF_US — Stock Titan

CRDF SEC Filings - Cardiff Oncology Inc 10-K, 10-Q, 8-K Forms

Revise las presentaciones ante la SEC de Cardiff Oncology (CRDF) con resúmenes de IA, incluidos los informes 10-K, 10-Q y 8-K sobre ensayos de onvansertib, finanzas, gobernanza y factores de riesgo clave.

23/04/2026 CRDF_US — Stock Titan

[ARS] Cardiff Oncology, Inc. SEC Filing

23/04/2026 CRDF_US — TradingView

CRDF Q1'26 Earnings: revenue estimate is 88.57K USD

23/04/2026 CRDF_US — Stock Titan

[DEF 14A] Cardiff Oncology, Inc. Definitive Proxy Statement

22/04/2026 CRDF_US — laocai.gov.vn

CRDF (Cardiff Oncology Inc.) reports narrower than expected Q4 2025 loss, shares climb 4.29% on positive investor sentiment. - Buyback Report

22/04/2026 CRDF_US — news.google.com

CRDF (Cardiff Oncology Inc.) reports narrower than expected Q4 2025 loss, shares climb 4.29% on positive investor sentiment. - Hold Rating

22/04/2026 CRDF_US — Investing.com Nigeria

Cardiff Oncology to present colorectal cancer trial data at ASCO By Investing.com